GT201700048A - Terapias de combinación con anticuerpos anti-cd38 - Google Patents
Terapias de combinación con anticuerpos anti-cd38Info
- Publication number
- GT201700048A GT201700048A GT201700048A GT201700048A GT201700048A GT 201700048 A GT201700048 A GT 201700048A GT 201700048 A GT201700048 A GT 201700048A GT 201700048 A GT201700048 A GT 201700048A GT 201700048 A GT201700048 A GT 201700048A
- Authority
- GT
- Guatemala
- Prior art keywords
- antibodies
- combination therapies
- present
- invention refers
- retinoic acid
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title abstract 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 abstract 1
- 229930002330 retinoic acid Natural products 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A TERAPIAS DE COMBINACIÓN CON ANTICUERPOS ANTI-CD38 Y EL ÁCIDO ALL-TRANS RETINOICO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047877P | 2014-09-09 | 2014-09-09 | |
US201462087287P | 2014-12-04 | 2014-12-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201700048A true GT201700048A (es) | 2019-08-21 |
Family
ID=55436472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201700048A GT201700048A (es) | 2014-09-09 | 2017-03-09 | Terapias de combinación con anticuerpos anti-cd38 |
Country Status (26)
Country | Link |
---|---|
US (2) | US20160067205A1 (es) |
EP (1) | EP3191187B1 (es) |
JP (2) | JP6707531B2 (es) |
KR (1) | KR102586588B1 (es) |
CN (1) | CN108064182B (es) |
AU (1) | AU2015315396B2 (es) |
BR (1) | BR112017004614A2 (es) |
CA (1) | CA2960494C (es) |
CL (1) | CL2017000559A1 (es) |
CR (1) | CR20170086A (es) |
EA (1) | EA035979B1 (es) |
EC (1) | ECSP17021175A (es) |
ES (1) | ES2890669T3 (es) |
GT (1) | GT201700048A (es) |
HK (1) | HK1255599A1 (es) |
IL (1) | IL251033B (es) |
MA (1) | MA40608A (es) |
MX (1) | MX2017003115A (es) |
MY (1) | MY192918A (es) |
NI (1) | NI201700027A (es) |
PE (1) | PE20170676A1 (es) |
PH (1) | PH12017500442A1 (es) |
SG (1) | SG11201701867SA (es) |
UA (1) | UA122212C2 (es) |
WO (1) | WO2016040294A2 (es) |
ZA (1) | ZA201702483B (es) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037929B1 (ru) * | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
RS59769B1 (sr) | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP2943511B1 (en) | 2013-01-14 | 2019-08-07 | Xencor, Inc. | Novel heterodimeric proteins |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
MX2016012578A (es) | 2014-03-28 | 2017-04-13 | Xencor Inc | Anticuerpos biespecificos que se unen a cd38 y cd3. |
AU2015315396B2 (en) | 2014-09-09 | 2020-10-08 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EA037065B1 (ru) | 2014-11-26 | 2021-02-01 | Ксенкор, Инк. | Гетеродимерные антитела, связывающие cd3 и cd38 |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
MX2017014396A (es) | 2015-05-13 | 2018-03-23 | Morphosys Ag | Tratamiento de mieloma multiple. |
UA124143C2 (uk) | 2015-05-20 | 2021-07-28 | Янссен Байотек, Інк. | Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень |
CA2990406A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
SI3370770T1 (sl) | 2015-11-03 | 2021-03-31 | Janssen Biotech, Inc. | Subkutane formulacije protiteles proti CD38 in njihove uporabe |
KR20180085800A (ko) | 2015-12-07 | 2018-07-27 | 젠코어 인코포레이티드 | Cd3 및 psma에 결합하는 이종이합체성 항체 |
TWI724046B (zh) * | 2016-04-06 | 2021-04-11 | 美商健生生物科技公司 | 以抗cd38抗體與生存素抑制劑於血紅素惡性腫瘤之組合治療 |
AU2017285218A1 (en) | 2016-06-14 | 2018-12-06 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
TWI781108B (zh) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗gprc5d抗體、結合gprc5d與cd3之雙特異性抗原結合分子及其用途 |
TW201823471A (zh) * | 2016-10-06 | 2018-07-01 | 美商錫羅斯製藥公司 | 以視黃酸受體-α促效劑及抗CD38抗體治療病患之方法 |
EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
EP3706785A4 (en) * | 2017-11-10 | 2021-08-04 | Actinium Pharmaceuticals, Inc. | COMBINATION THERAPY FOR TREATMENT OF A HEMATOLOGICAL DISEASE |
CA3130695A1 (en) | 2019-02-27 | 2020-09-03 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies |
CN113993543A (zh) | 2019-06-10 | 2022-01-28 | 武田药品工业株式会社 | 使用抗cd38抗体的组合疗法 |
JP2022553803A (ja) | 2019-11-06 | 2022-12-26 | ジェネンテック, インコーポレイテッド | 血液がんの処置のための診断方法及び治療方法 |
GB201916150D0 (en) * | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
CN116406291A (zh) | 2020-10-05 | 2023-07-07 | 基因泰克公司 | 用抗fcrh5/抗cd3双特异性抗体进行治疗的给药 |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
JP2024509274A (ja) | 2021-03-10 | 2024-02-29 | ゼンコア インコーポレイテッド | Cd3及びgpc3に結合するヘテロ二量体抗体 |
TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法 |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
WO1992001049A2 (en) | 1990-07-13 | 1992-01-23 | The General Hospital Corporation | Cd53 cell surface antigen and use thereof |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
US5837242A (en) | 1992-12-04 | 1998-11-17 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994017184A1 (en) | 1993-01-29 | 1994-08-04 | Schering Corporation | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
JP4233608B2 (ja) | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | 自己抗体測定方法 |
PT932417E (pt) | 1996-10-17 | 2003-07-31 | Immunomedics Inc | Conjugado de toxina nao antigenico e proteina de fusao de sistema receptor de interiorizacao |
WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
ATE302217T1 (de) | 1997-05-02 | 2005-09-15 | Us Gov Health & Human Serv | Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen |
CA2329940A1 (en) | 1998-06-05 | 1999-12-09 | Mayo Foundation For Medical Education And Research | Use of genetically engineered antibodies to cd38 to treat multiple myeloma |
US7223397B1 (en) * | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
CA2412901A1 (en) | 2000-06-22 | 2001-12-27 | Idec Pharmaceutical Corporation | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
CA2424643A1 (en) | 2000-10-17 | 2002-04-25 | Trudeau Institute, Inc. | Cd38 modulated chemotaxis |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
DE60317677T2 (de) * | 2002-06-13 | 2008-10-30 | Crucell Holland B.V. | Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung |
DK2163643T3 (en) | 2003-03-05 | 2015-03-23 | Halozyme Inc | Soluble hyaluronidaseglycoprotein (sHASEGP), process for preparing the same, pharmaceutical compositions and uses thereof covered |
CN1829741A (zh) | 2003-05-30 | 2006-09-06 | 健泰科生物技术公司 | 利用抗-vegf抗体的治疗 |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
CA2542840A1 (en) | 2003-10-22 | 2005-05-12 | University Of Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
KR101128777B1 (ko) | 2003-11-04 | 2012-04-13 | 조마 테크놀로지 리미티드 | 다발성 골수종을 치료하기 위한 길항제 항-cd40단클론성 항체의 용도 |
JP4712724B2 (ja) | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | CD1aに対するヒト結合分子 |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
SG142330A1 (en) | 2004-02-06 | 2008-05-28 | Morphosys Ag De | Anti-cd38 human antibodies and uses therefor |
WO2006125640A2 (en) | 2005-05-24 | 2006-11-30 | Morphosys Ag | Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38 |
EA037929B1 (ru) * | 2005-03-23 | 2021-06-08 | Генмаб А/С | Антитела к cd38 человека и их применение |
EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
CN106434683B (zh) | 2005-10-12 | 2020-03-13 | 莫佛塞斯公司 | 特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定 |
EP1968636A4 (en) | 2005-12-09 | 2010-06-02 | Seattle Genetics Inc | METHOD OF USE OF CD40 BONDING AGENTS |
AR060070A1 (es) | 2006-03-24 | 2008-05-21 | Merck Patent Gmbh | Dominios proteicos heterodimericos obtenidos por ingenieria |
JP2009541275A (ja) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | 二重特異性抗体の生産 |
DK2049109T3 (en) | 2006-08-02 | 2016-01-11 | Sunesis Pharmaceuticals Inc | Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia |
WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
CA2664740C (en) | 2006-09-26 | 2021-11-16 | Genmab A/S | Combination treatment of cd38-expressing tumors |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
US20100330081A1 (en) | 2007-06-01 | 2010-12-30 | Biogen Idec Ma Inc. | Cripto binding molecules |
US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
RU2491095C2 (ru) | 2007-11-09 | 2013-08-27 | Новартис Аг | Применения анти-cd40-антител |
WO2009074807A2 (en) | 2007-12-12 | 2009-06-18 | Imperial Innovations Limited | Methods |
EP2231904B1 (en) | 2007-12-19 | 2016-01-13 | Janssen Biotech, Inc. | Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
JP2011517320A (ja) | 2008-03-03 | 2011-06-02 | ダイアックス コーポレーション | メタロプロテアーゼ9結合タンパク質およびメタロプロテアーゼ2結合タンパク質 |
MX2010009647A (es) | 2008-03-25 | 2010-09-28 | Roche Glycart Ag | Uso de un anticuerpo anti-cd20 de tipo ii con citotoxicidad celular dependiente del anticuerpo aumentada en combinacion con ciclofosfamida, vincristina y doxorubicina para el tratamiento de linfoma no hodgkiniano. |
KR20100135291A (ko) | 2008-04-14 | 2010-12-24 | 할로자임, 아이엔씨 | 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도 |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
HUE028175T2 (en) | 2008-11-07 | 2016-12-28 | Amgen Res (Munich) Gmbh | Treatment of acute lymphoblastic leukemia |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2424567B1 (en) | 2009-04-27 | 2018-11-21 | OncoMed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US8865710B2 (en) | 2009-05-14 | 2014-10-21 | Ambit Biosciences Corporation | Methods of treating proliferative diseases |
WO2011034604A2 (en) | 2009-09-17 | 2011-03-24 | Baxter Healthcare, S.A. | Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
DK2486141T3 (en) | 2009-10-07 | 2018-04-23 | Macrogenics Inc | FC-REGION-CONTAINING POLYPEPTIDES THAT PROVIDE IMPROVED EFFECTOR FUNCTION BASED ON CHANGES OF THE SCOPE OF FUCOSYLATION AND PROCEDURES FOR THEIR USE |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
WO2011121588A1 (en) | 2010-03-29 | 2011-10-06 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
KR101930964B1 (ko) | 2010-04-20 | 2018-12-19 | 젠맵 에이/에스 | 이종이량체 항체 fc-함유 단백질 및 그의 생산 방법 |
WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
RS59769B1 (sr) | 2010-06-09 | 2020-02-28 | Genmab As | Antitela protiv humanog cd38 |
EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
MX350540B (es) * | 2010-09-27 | 2017-09-08 | Morphosys Ag | Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl. |
DK2635607T3 (da) | 2010-11-05 | 2019-11-18 | Zymeworks Inc | Stabilt heterodimert antistofdesign med mutationer i fc-domænet |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
CL2013001944A1 (es) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune. |
ES2543569T3 (es) | 2011-03-23 | 2015-08-20 | Amgen Inc. | Inhibidores duales tricíclicos condensados de CDK 4/6 y FLT3 |
EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
EA201700111A1 (ru) | 2011-10-28 | 2018-02-28 | Тева Фармасьютикал Австралия Пти Лтд | Полипептидные конструкции и их применение |
BR112014028826A8 (pt) | 2012-05-15 | 2021-07-20 | Bristol Myers Squibb Co | anticorpos monoclonais, uso de anticorpos anti-pd1, anti-pd-l1 e anti-ctla-4 em imunoterapia e tratamento de câncer, bem como kits e processo de seleção de indivíduo para tratamento com anticorpo anti-pd-1 |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
EP2900232B1 (en) * | 2012-09-25 | 2017-11-15 | MorphoSys AG | Combinations and uses thereof |
WO2014068114A1 (en) | 2012-11-05 | 2014-05-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
WO2014142220A1 (ja) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | 抗腫瘍剤 |
US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
CA2909952C (en) | 2013-04-29 | 2021-10-12 | Teva Pharmaceuticals Australia Pty Ltd. | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b |
US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
JP2016534090A (ja) | 2013-07-15 | 2016-11-04 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Cd38アゴニストの医学的使用 |
EP3805266A1 (en) | 2013-10-31 | 2021-04-14 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
EP3066125A2 (en) | 2013-11-06 | 2016-09-14 | Boehringer Ingelheim International GmbH | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
WO2015195556A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells |
WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
AU2015315396B2 (en) | 2014-09-09 | 2020-10-08 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
PE20171094A1 (es) | 2014-12-04 | 2017-08-07 | Janssen Biotech Inc | Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda |
UA124143C2 (uk) | 2015-05-20 | 2021-07-28 | Янссен Байотек, Інк. | Антитіла до cd38 для лікування амілоїдозу, викликаного відкладеннями легких ланцюгів імуноглобулінів, і інших cd38-позитивних злоякісних гематологічних новоутворень |
CA2990406A1 (en) | 2015-06-22 | 2016-12-29 | Janssen Biotech, Inc. | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
PE20181090A1 (es) | 2015-06-24 | 2018-07-09 | Janssen Biotech Inc | Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38 |
SI3370770T1 (sl) | 2015-11-03 | 2021-03-31 | Janssen Biotech, Inc. | Subkutane formulacije protiteles proti CD38 in njihove uporabe |
US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
EP3474895A1 (en) | 2016-06-28 | 2019-05-01 | UMC Utrecht Holding B.V. | TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38 |
US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
WO2019089832A1 (en) | 2017-10-31 | 2019-05-09 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
-
2015
- 2015-09-08 AU AU2015315396A patent/AU2015315396B2/en active Active
- 2015-09-08 CA CA2960494A patent/CA2960494C/en active Active
- 2015-09-08 CR CR20170086A patent/CR20170086A/es unknown
- 2015-09-08 US US14/847,428 patent/US20160067205A1/en not_active Abandoned
- 2015-09-08 ES ES15839752T patent/ES2890669T3/es active Active
- 2015-09-08 MA MA040608A patent/MA40608A/fr unknown
- 2015-09-08 WO PCT/US2015/048899 patent/WO2016040294A2/en active Application Filing
- 2015-09-08 CN CN201580060898.4A patent/CN108064182B/zh active Active
- 2015-09-08 MX MX2017003115A patent/MX2017003115A/es unknown
- 2015-09-08 JP JP2017513177A patent/JP6707531B2/ja active Active
- 2015-09-08 KR KR1020177009199A patent/KR102586588B1/ko active IP Right Grant
- 2015-09-08 PE PE2017000431A patent/PE20170676A1/es unknown
- 2015-09-08 MY MYPI2017700796A patent/MY192918A/en unknown
- 2015-09-08 BR BR112017004614-8A patent/BR112017004614A2/pt not_active Application Discontinuation
- 2015-09-08 SG SG11201701867SA patent/SG11201701867SA/en unknown
- 2015-09-08 EA EA201790548A patent/EA035979B1/ru unknown
- 2015-09-08 UA UAA201703276A patent/UA122212C2/uk unknown
- 2015-09-08 EP EP15839752.1A patent/EP3191187B1/en active Active
-
2016
- 2016-12-21 US US15/386,391 patent/US10604580B2/en active Active
-
2017
- 2017-03-08 IL IL251033A patent/IL251033B/en unknown
- 2017-03-08 NI NI201700027A patent/NI201700027A/es unknown
- 2017-03-08 CL CL2017000559A patent/CL2017000559A1/es unknown
- 2017-03-09 PH PH12017500442A patent/PH12017500442A1/en unknown
- 2017-03-09 GT GT201700048A patent/GT201700048A/es unknown
- 2017-04-06 EC ECIEPI201721175A patent/ECSP17021175A/es unknown
- 2017-04-07 ZA ZA2017/02483A patent/ZA201702483B/en unknown
-
2018
- 2018-11-19 HK HK18114728.0A patent/HK1255599A1/zh unknown
-
2020
- 2020-05-18 JP JP2020086765A patent/JP2020143108A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201700048A (es) | Terapias de combinación con anticuerpos anti-cd38 | |
GT201600172A (es) | Terapias de combinacion con anticuerpos anti-cd38 | |
DOP2018000181A (es) | Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-cd38 e inhibidores de survivina | |
PH12017502104A1 (en) | Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies | |
CL2016002455A1 (es) | Anticuerpos multiespecíficos. | |
CO2017003118A2 (es) | Arnés de seguridad con un ensamblaje de distribución de peso”. | |
AR097668A1 (es) | Colorante-polímero | |
AR096154A1 (es) | Colorantes bisazoicos alcoxilados | |
DK3204357T3 (da) | Fluorescerende, syntetiske retinoider | |
TWD173284S (zh) | 模型槍 | |
TWD166602S (zh) | 警示燈 | |
CR20140456S (es) | Grúa de pórtico | |
TWD168167S (zh) | 攝影機 | |
AU358715S (en) | Backpack | |
TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها | |
TN2014000355A1 (fr) | طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية | |
TWD160644S (zh) | 警示燈 | |
TN2013000364A1 (fr) | تصميم جديد لطائرة مدنية ذات مقعد واحد و انظمة سلامة متطورة |